Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProtAffin has received new patent from the European Patent Office (EPO) for its CellJammer discovery technology.
Subscribe to our email newsletter
CellJammer discovery technology helps in discovering and developing new biopharmaceuticals.
ProtAffin claims the technology enables the company to discover and develop biopharmaceuticals with a novel mechanism of action which may avoid a number of the problems currently experienced by industry using more traditional modalities to target chemokine activity.
ProtAffin CSO Andreas Kungl said they have identified a novel way to down-regulate chemokine activity by using biopharmaceuticals based on decoy chemokines which target glycans.
"Following the broad grant of claims for our unique approach to discovering biopharmaceuticals in respiratory and AAID, we look forward to discussing with interested Pharmaceutical and Biotech companies the potential to collaborate in the discovery and development of differentiated biologics which could offer specific advantages over monoclonal antibodies and small molecule therapeutics," Kungl said.